+91-8668442535

Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Docusate Sodium, Others), By Prescription Type (Prescribed, Over The Counter) - Growth, Future Prospects And Competitive Analysis, 2018 – 2026

The mechanism of action of opioid analgesics through binding to the mu, delta, and kappa receptors present in the brain by crossing the blood-brain barrier and giving the desired analgesic effect to treat non-cancer pain. In addition, the opioids bind to the mu receptors present in the gastrointestinal tract, which results in contraction of the smooth muscles and alters the peristaltic movement causing constipation. Usually, the patients opt for over-the-counter osmotic laxatives and stimulant cathartics, which have been beneficial in providing relief from constipation in patients taking opioid analgesics for 3-4 weeks. In patients seeking palliative care, doctors prescribe mu-receptor antagonists and prostaglandin derivatives to cure opioid-induced constipation.

 

The drug types considered for the scope of the report are segmented as methylnaltrexone bromide, lubiprostone, naloxegol, naldemedine, docusate sodium, and others. The prescription types segment includes prescribed and over-the-counter drugs. CAGR and market size are given for the above-mentioned segments.

 

The market size and CAGR are given for the geographical regions along with their major countries in the scope of the report.The company profiles section provides useful information such as the product portfolio exhibiting the diverse range of over-the-counter drugs available such as osmotic laxatives, stimulant cathartics, herbal extracts, and prescribed drugs used to relieve constipation induced due to the use of opioid analgesics. Recent developments give brief elucidation of the latest mergers and acquisitions and strategic events between key players.

 

The competitive analysis presented in this report gives an idea regarding the competitive environment prevalent in the opioid-induced constipation drugs market. This report is an important market assessment tool that helps in understanding the latest market trend existing in the opioid-induced constipation drugs market by supplementing the market size and CAGR for drug type and prescription type. The key players pioneering in the opioid-induced constipation drugs market are AstraZeneca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer, Inc., Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Shionogi & Co Ltd., Sucampo Pharmaceuticals, Inc. and Synergy Pharmaceuticals, Inc.

 

Based on drug type, the opioid-induced constipation drugs market is categorized into:

  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Naldemedine
  • Docusate Sodium
  • Others

 

According to the World Health Organization 2015 report, there has been a significant increase in the number of opioid analgesics prescribed for non-cancer pain in the last decade. Each year, approximately 40 million people receive palliative care throughout the globe to reduce pain intensity and improve patients’ quality of life. The factors responsible for the growth of non-cancer pain are Kellgren Lawrence grade 3 osteoarthritis, neuropathic pain, rheumatoid arthritis, and severe fibromyalgia.

 

As per the research cited by the Center for Disease Control and Prevention (2015), more than 40% of the patients receiving opioid analgesics suffer from constipation and other gastrointestinal complications. Currently, drugs such as osmotic laxatives and stimulant cathartics dominate the market as the patients usually prefer over-the-counter products to get relief from constipation. Physicians usually prescribe OTC laxatives along with opioid analgesics on account of their safety and fewer gastrointestinal complications.

 

Naloxegol will register significant growth during the forecast period from 2018 to 2026 on account of the rising prevalence of non-cancer pain diseases such as osteoarthritis, fibromyalgia, etc. Moreover, enhanced drug efficacy and fewer drug-related adverse events such as diarrhea and bloating in comparison to other mu receptor antagonists (e.g., methylnaltrexone bromide) drive naloxegol’s market demand. Recently naldemedine manufactured by Shionogi, Inc. has received FDA approval for the treatment of OIC and will register excellent growth during the forecast period. The key players pioneering in the opioid-induced constipation drugs market are AstraZeneca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer, Inc., Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Shionogi & Co Ltd., Sucampo Pharmaceuticals, Inc. and Synergy Pharmaceuticals, Inc.

 

For the purpose of this study, the global opioid-induced constipation drugs market is categorized into the following regional and country-specific markets:

North America

  • The U.S.
  • Canada

Europe

  • The U.K.
  • Germany
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

The Middle East and Africa

  • GCC
  • Rest of the Middle East and Africa

North America currently leads the opioid-induced constipation drugs market due to the increasing number of patients suffering from non-cancer pain and rising public health awareness resulting in early diagnosis and treatment for osteoarthritis and rheumatoid arthritis. The European opioid-induced constipation drug market is driven by an increasing number of patients seeking palliative care in rehabilitation centers and the rising geriatric population suffering from non-cancer pain. The Asia Pacific is set to register significant growth in opioids induced constipation drugs market on account of the huge population base suffering from chronic diseases such as rheumatoid arthritis and fibromyalgia associated with strenuous working conditions. The rising use of opioids due to easy availability and poor regulation drives the Asia Pacific opioids-induced constipation drugs market.

 

Based on prescription type, the opioid-induced constipation drugs market is categorized into:

  • Prescribed
  • Branded
  • Generic
  • Over the Counter

 

The American Society of Addiction Medicine (2016 facts) states that approximately 2 million U.S. citizens have a substance use disorder related to prescribed opioid analgesics. The World Health Organization 2015 report mentions that 15.3 million people throughout the globe are suffering from opioid use disorder resulting in severe constipation. In the present scenario, prescribed drugs are dominating the market on account of an increasing number of patients showing resistance to over-the-counter laxatives and cathartics.

 

Moreover, opioid analgesics bind to the mu receptors of the gastrointestinal tract, causing severe contraction of smooth muscles, altering the peristaltic activity of the gut motility, thus leading to chronic constipation. Physicians usually prescribe branded drugs such as methylnaltrexone bromide and naloxegol (mu-receptor antagonists) and prostaglandin derivatives such as lubiprostone to gain immediate relief from constipation by increasing fluid retention and stool softening. Over-the-counter (OTC) osmotic laxatives and stimulant cathartics are the drugs of the first choice by patients to treat constipation. OTC products have shown good results in patients taking opioid analgesics for less than four weeks.

 

Frequently asked questions

The market for Opioid Induced Constipation (OIC) Drugs is expected to reach USD US$ 3,770.4 Mn in 2028.

The Opioid Induced Constipation (OIC) Drugs market is expected to see significant CAGR growth over the coming years, at 4.92%.

The report is forcasted from 2018-2026

The base year of this report is 2021.

AstraZeneca plc, Business Description, Financial Information,Product Portfolio,Key Developments,Cubist Pharmaceuticals,Daiichi Sankyo Co., Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Feb 2018
Category:  Pharmaceuticals
Report ID:   57737
Report Format:   PDF
Pages:   120
Rating:    4.3 (55)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support